Cargando…

Cytomegalovirus Infection after Allogeneic Hematopoietic Cell Transplantation under 100-Day Letermovir Prophylaxis: A Real-World 1-Year Follow-Up Study

The prevention and management of cytomegalovirus (CMV) reactivation is important to improve the outcomes of allogeneic hematopoietic cell transplantation (allo-HCT) recipients. The aim of this study was to analyze real-world data regarding the incidence and characteristics of CMV infections until 1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nho, Dukhee, Lee, Raeseok, Cho, Sung-Yeon, Lee, Dong-Gun, Kim, Eun-Jin, Park, Silvia, Lee, Sung-Eun, Cho, Byung-Sik, Kim, Yoo-Jin, Lee, Seok, Kim, Hee-Je
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10536589/ https://www.ncbi.nlm.nih.gov/pubmed/37766290 http://dx.doi.org/10.3390/v15091884

Ejemplares similares

Genetic Variants Associated with Drug Resistance of Cytomegalovirus in Hematopoietic Cell Transplantation Recipients
por: Chae, Seungwan, et al.
Publicado: (2023)

Letermovir for cytomegalovirus prophylaxis
Publicado: (2019)

Impact of cytomegalovirus reactivation on relapse and survival in patients with acute leukemia who received allogeneic hematopoietic stem cell transplantation in first remission
por: Yoon, Jae-Ho, et al.
Publicado: (2016)

Infections of Venetoclax-Based Chemotherapy in Acute Myeloid Leukemia: Rationale for Proper Antimicrobial Prophylaxis
por: Lee, Raeseok, et al.
Publicado: (2021)

A Mortality Analysis of Letermovir Prophylaxis for Cytomegalovirus (CMV) in CMV-seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation
por: Ljungman, Per, et al.
Publicado: (2020)

928. Concordance with Institutional Guidelines for Letermovir Cytomegalovirus Infection Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant Recipients
por: Peterson-Weber, Alex, et al.
Publicado: (2023)

SOCS1 and SOCS3 are expressed in mononuclear cells in human cytomegalovirus viremia after allogeneic hematopoietic stem cell transplantation
por: Shin, Seung-Hwan, et al.
Publicado: (2015)

Cost-effectiveness analysis of the use of letermovir for the prophylaxis of cytomegalovirus in adult cytomegalovirus seropositive recipients undergoing allogenic hematopoietic stem cell transplantation in Italy
por: Restelli, Umberto, et al.
Publicado: (2019)

Letermovir prophylaxis is effective in preventing cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation: single-center real-world data
por: Derigs, Patrick, et al.
Publicado: (2020)

Letermovir Prophylaxis for Cytomegalovirus Infection in Allogeneic Stem Cell Transplantation: A Real-World Experience
por: Martino, Massimo, et al.
Publicado: (2021)

A Mortality Analysis of the Cytomegalovirus (CMV) Infection Letermovir Prophylaxis Trial in CMV-Seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation (HCT)
por: Maertens, Johan, et al.
Publicado: (2017)

Cost Effectiveness of Letermovir for Cytomegalovirus Prophylaxis Compared with Pre-Emptive Therapy in Allogeneic Hematopoietic Stem Cell Transplant Recipients in the United States
por: Sepassi, Aryana, et al.
Publicado: (2023)

2648. Terminating the Troll of Transplantation: Letermovir for Cytomegalovirus Prophylaxis
por: Hedvat, Jason, et al.
Publicado: (2019)

Cytomegalovirus Infections after Hematopoietic Stem Cell Transplantation: Current Status and Future Immunotherapy
por: Cho, Sung-Yeon, et al.
Publicado: (2019)

Letermovir for Prophylaxis and Pre-emptive Therapy of Cytomegalovirus Infection in Paediatric Allogeneic Haematopoietic Cell Transplant Patients
por: Körholz, Katharina F., et al.
Publicado: (2022)

CMV Infection After Letermovir Primary Prophylaxis Discontinuation in Allogeneic Hematopoietic Cell Transplant Recipients
por: Chavaz, Lara, et al.
Publicado: (2023)

Letermovir and its role in the prevention of cytomegalovirus infection in seropositive patients receiving an allogeneic hematopoietic cell transplant
por: Shigle, Terri Lynn, et al.
Publicado: (2020)

Therapeutic Drug Monitoring of Orally Administered Letermovir Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant Recipients
por: Royston, Léna, et al.
Publicado: (2022)

Advances in prophylaxis and treatment of invasive fungal infections: perspectives on hematologic diseases
por: Ahn, Hyojin, et al.
Publicado: (2022)

Letermovir for Cytomegalovirus Prevention in Patients Undergoing Hematopoietic Cell Transplantation
por: Daniels, Kori, et al.
Publicado: (2019)

Hepatic veno-occlusive disease resulting in tacrolimus toxicity after allogeneic hematopoietic stem cell transplantation
por: Shin, Seung-Hwan, et al.
Publicado: (2013)

Fast breakthrough of resistant cytomegalovirus during secondary letermovir prophylaxis in a hematopoietic stem cell transplant recipient
por: Jung, Susanne, et al.
Publicado: (2019)

Impact of Letermovir Use for Cytomegalovirus Prophylaxis on Re-Hospitalization Following Allogeneic Hematopoietic Stem Cell Transplantation: An Analysis of a Phase III Randomized Clinical Trial
por: Golan, Yoav, et al.
Publicado: (2021)

926. Risk factors for post-letermovir cytomegalovirus (CMV) reactivation in allogeneic hematopoietic stem cell transplant (HSCT) recipients
por: Mendoza, Maria Alejandra, et al.
Publicado: (2023)

The salvage role of allogeneic hematopoietic stem-cell transplantation in relapsed/refractory diffuse large B cell lymphoma
por: Min, Gi-June, et al.
Publicado: (2023)

Cytomegalovirus reactivation under pre-emptive therapy following allogeneic hematopoietic stem cell transplant: Pattern, survival, and risk factors in the Republic of Korea
por: Kang, Ka-Won, et al.
Publicado: (2023)

Real-World Outcomes Associated With Letermovir Use for Cytomegalovirus Primary Prophylaxis in Allogeneic Hematopoietic Cell Transplant Recipients: A Systematic Review and Meta-analysis of Observational Studies
por: Vyas, Ami, et al.
Publicado: (2022)

571. “Real world” Impact of Letermovir for Prevention of Cytomegalovirus Infection in Hematopoietic-Cell Transplantation
por: Loecher, Alyssa M, et al.
Publicado: (2020)

Predictors of breakthrough clinically significant cytomegalovirus infection during letermovir prophylaxis in high‐risk hematopoietic cell transplant recipients
por: Royston, Léna, et al.
Publicado: (2021)

Letermovir Prophylaxis and Cytomegalovirus Reactivation in Adult Hematopoietic Cell Transplant Recipients with and without Acute Graft Versus Host Disease
por: Wolfe, Delaney, et al.
Publicado: (2021)

1995. Duration of letermovir primary prophylaxis in hematopoietic cell transplant recipients at high risk for cytomegalovirus infections and impact on outcomes
por: Febres-Aldana, Anthony J, et al.
Publicado: (2023)

Feasible outcome of blinatumomab followed by allogeneic hematopoietic cell transplantation for adults with Philadelphia chromosome‐negative acute lymphoblastic leukemia in first salvage
por: Yoon, Jae‐Ho, et al.
Publicado: (2019)

HLA-mismatched donor and high ferritin level showed poor clinical outcomes after allogeneic hematopoietic cell transplantation in patients with advanced myelofibrosis
por: Yoon, Jae-Ho, et al.
Publicado: (2020)

The demanding attention of tuberculosis in allogeneic hematopoietic stem cell transplantation recipients: High incidence compared with general population
por: Lee, Hyo-Jin, et al.
Publicado: (2017)

Proven Cytomegalovirus Colitis Associated with Dasatinib Administration in Two Pediatric Allogeneic Hematopoietic Stem Cell Transplantation Recipients
por: Kim, Jeong Min, et al.
Publicado: (2023)

Experiences of allogeneic hematopoietic cell transplantation following non-myeloablative conditioning regimen in severely comorbid patients with myelofibrosis: case series with a patient presenting with extensive extramedullary hematopoiesis
por: Yoon, Jae-Ho, et al.
Publicado: (2020)

Extended-duration letermovir prophylaxis for cytomegalovirus infection after cord blood transplantation in adults
por: Politikos, Ioannis, et al.
Publicado: (2022)

Expression of SOCS1 and SOCS3 genes in human graft-versus-host disease after allogeneic hematopoietic stem cell transplantation
por: Lee, Tae Hyang, et al.
Publicado: (2013)

Risk factors predicting graft-versus-host disease and relapse-free survival after allogeneic hematopoietic stem cell transplantation in relapsed or refractory non-Hodgkin’s lymphoma
por: Jeon, Young-Woo, et al.
Publicado: (2019)

Clinical Usefulness of Monitoring Cytomegalovirus-Specific Immunity by Quantiferon-CMV in Pediatric Allogeneic Hematopoietic Stem Cell Transplantation Recipients
por: Lee, Sae-Mi, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_nqql8ml833mnntup11hgo9sgig